전 세계 유전성 강직성 하반신마비(HSP) 시장 규모는 예측 기간인 2025-2032년 동안 14.65%의 CAGR로 2024년 1억 1,590만 달러에서 2032년 3억 4,600만 달러로 성장할 것으로 예상됩니다. 시장 개척을 뒷받침하는 것은 HSP 사례의 증가, 유전자 연구의 발전, 지원적인 규제 조치, 연구개발 활동에 대한 투자 증가입니다. 또한, 유전자 편집 플랫폼과 신경 재활 솔루션의 발전도 시장 성장을 촉진하는 데 중요한 역할을 할 것으로 예상됩니다.
첨단 진단 솔루션과 유전자 치료에 대한 관심이 높아지면서 시장 성장과 확장을 뒷받침하고 있습니다. 전장유전체 시퀀싱과 차세대 시퀀싱은 조기 치료 개입을 가능하게 하고 진단 정확도를 향상시키고 있습니다. 연구자들은 또한 HSP의 근본적인 원인을 해결하기 위해 유전자 침묵 및 대체 전략을 모색하고 있습니다. 제약회사와 학술 연구기관들은 새로운 치료법의 안전성과 유효성을 시험하고, 유전형과 표현형의 상관관계를 이해하기 위해 전임상 연구 활동에 투자하고 있습니다.
또한, 전 세계 의료 시스템은 희귀질환 및 신경질환의 진단 효율성과 치료법 개선에 집중하고 있으며, 이는 시장 확대를 뒷받침하고 있습니다. 각국 정부는 HSP를 포함한 희귀질환의 위협 증가에 대응하기 위한 정책을 시행하고 있으며, 제약회사에 인센티브를 제공하기 위해 세액공제, 조기 승인, 연구 보조금 등을 제공하고 있습니다.
세계의 유전성 강직성 하반신마비(HSP) 시장에 대해 조사했으며, 시장 개요와 함께 약제별, 중증도별, 유통 채널별, 지역별 동향, 시장 진입 기업 프로파일 등의 정보를 전해드립니다.
Global hereditary spastic paraplegia (HSP) market is projected to witness a CAGR of 14.65% during the forecast period 2025-2032, growing from USD 115.90 million in 2024 to USD 346 million in 2032. The market's growth is supported by the rising cases of HSP, advancements in genetic research, supportive regulatory measures, and rising investments towards research and development activities. Additionally, advancements in gene editing platforms and neurorehabilitation solutions are also expected to play a significant role in driving the growth of the market.
Increasing emphasis on advanced diagnostic solutions and gene therapies is also supporting the market's growth and expansion. Whole-exome sequencing and next-generation sequencing are allowing early therapeutic interventions and improving diagnostic accuracy. Researchers are also exploring gene silencing and replacement strategies to address the underlying cause of HSP. Pharmaceutical companies and academic and research institutions are investing in preclinical research activities to test the safety and efficacy of novel therapies and understand genotype-phenotype correlations.
Moreover, healthcare systems across the globe are focusing on improving diagnostic efficiency and treatments for rare diseases and neurological disorders, supporting the market's expansion. Various governments are implementing policies to combat the growing threat of rare diseases, including HSP and providing tax credits, accelerated approvals, and research grants to incentivize pharmaceutical companies.
Increasing Regulatory Support Boosts Market Growth
Increasing support from different regulatory bodies such as the Food and Drug Administration (FDA) is accelerating the clinical evaluation and development of innovative therapeutic solutions for treating and managing neurogenetic disorders. For instance, in May 2025, BlackfinBio Limited received approval from the US FDA to begin phase 1/2 clinical trial for adeno-associated virus (AAV) gene therapy targeting HSP, Type 47. The trial aims to assess the tolerability, safety, and efficacy of the AAV gene therapy in patients with HSP, Type 47. Such approvals validate scientific advancements and incentivize pharmaceutical companies to invest in research and development activities.
Additionally, the provision of rare pediatric disease status and orphan drug designation further encourage pharmaceutical companies to pursue novel therapeutic solutions by providing benefits such as financial incentives and market exclusivity. Such supportive initiatives foster collaboration between industry leaders, clinical centers, and academic institutions, resulting in the expedition of molecular and genetic discoveries, improving treatment outcomes and bolstering the availability of treatment options, positively influencing the market's expansion.
Rising Research Activities Support Market Expansion
Advances in molecular genetics and next-generation sequencing have already identified over 80 genetic causes of HSP, laying the groundwork for variant-specific therapies. Researchers across the globe are focusing on developing gene therapies for HSP. For instance, in January 2024, a team of researchers from the Korea Research Institute of Bioscience & Biotechnology (KRIBB) developed gene therapy for HSP. The team identified the role of ARL6IP1 gene in the onset of HSP. Their findings showed that ARL6IP1 is involved in maintaining homeostasis of cellular organelles and is located in the mitochondrial associated ER membrane. The presence of a robust research environment that fosters innovations and supports development of new therapies is allowing researchers to bridge the gaps in HSP care and develop disease modifying treatments.
Hospitals Pharmacies Account for Significant Share of the Market
The segment's dominance can be attributed to the central role played by hospitals and clinics in the management and treatment of HSP. The condition requires multidisciplinary care involving physiotherapies and neurologists, among other specialists, which is only available and effectively coordinated in hospitals and clinics. Additionally, hospitals and clinics also offer medication management and comprehensive patient monitoring, which is essential for diseases such as HSP. They are equipped with the necessary technology and professionals to handle complex cases, provide patient education to improve treatment adherence, and adjust treatment regimens. Additionally, hospitals algo participate in various clinical trials to elevate the understanding of different mechanisms associated with HSP, further strengthening the segment's position. For instance, Boston Children's Hospital is conducting an observational study to better understand the role of genetic factors in HSP. The study is estimated to conclude in April 2027.
North America Holds Major Market Share
The rapid growth of the market in North America can be attributed to the availability of high fundings for rare disease research, strong presence of leading market players, availability of advanced genetic testing services, and rising incidences of HSP. As per the estimates of the Spastic Paraplegia Foundation, in the United States the HSP incidence rate is approximately 20,000.
The strong presence of leading academic and research institutions and pharmaceutical companies is supporting innovations and new product launches, driving the market's growth and expansion. In countries such as the United States, supportive framework and initiatives including the Orphan Drug Act are enabling early-stage clinical research and providing financial incentives for HSP drug development. Additionally, the rising popularity of telehealth services is improving patient access to specialists and neurologists, especially in rural locations, allowing patients to receive timely diagnosis, supporting the market's expansion.
Future Market Scenario (2025 - 2032F)
The market is expected to witness significant growth over the forecast period, due to rising awareness, technological advancements, and increasing research in curative gene therapies. With rising investments from both private and public sectors, the focus on disease-modifying treatments is increasing, bolstering the availability of therapeutic solutions that tackle the root cause of the condition and just symptomatic management. Additionally, rising emphasis on research activities to bolster the availability of new treatments for HSP is also expected to propel the market's expansion. For instance, Shanghai Sixth People's Hospital, affiliated to Shanghai Jiao Tong University School of Medicine is conducting an interventional study to explore the safety and efficacy of calcium folinate for treating patients with spastic paraplegia 56. The study is estimated to conclude in May 2030. Additionally, advancements in AI-powered diagnostic and biomarker analysis are expected to support early disease detection, providing lucrative growth opportunities for the market.
Key Players Landscape and Outlook
The leading market players are focusing on conducting clinical trials, developing new therapies, and working on improving the understanding of the genetic factors responsible for HSP. The key players are also focusing on seeking investments to support their research and development activities and bolster the availability of novel therapeutic solutions. For instance, in December 2023, BlackfinBio Limited raised approximately USD 3.7 million in seed investment to advance treatments for HSP. Such investments are expected to accelerate the translation of laboratory discoveries to therapies, improving prospects for the patient population across the globe and allowing companies to expand their presence in the industry.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.